Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

BACKGROUND: Rash, liver dysfunction, and diarrhea are known major adverse events associated with erlotinib and gefitinib. However, clinical trials with gefitinib have reported different proportions of adverse events compared to trials with erlotinib. In an in vitro study, cytochrome P450 (CYP) 2D6 w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Suzumura, Tomohiro, Kimura, Tatsuo, Kudoh, Shinzoh, Umekawa, Kanako, Nagata, Misato, Matsuura, Kuniomi, Tanaka, Hidenori, Mitsuoka, Shigeki, Yoshimura, Naruo, Kira, Yukimi, Nakai, Toshiyuki, Hirata, Kazuto
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3536666/
https://ncbi.nlm.nih.gov/pubmed/23207012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-568
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares